Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07567521 is registered in ClinicalTrials.gov with C Ray Therapeutics as lead sponsor.

NCT NCT07567521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07567521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
C Ray Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 22, 2026
Completion date
December 30, 2029
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer